Related Experiment Videos
T cell targeting in cancer therapy
R L Bolhuis1, E Sturm, E Braakman
1Department of Immunology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Cancer Immunology, Immunotherapy : CII
|January 1, 1991
Summary
Bispecific antibodies harness the immune system to fight cancer by linking immune cells to tumor cells, activating a targeted attack with minimal toxicity. This immunotherapy approach offers a promising new avenue for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Bispecific antibodies are powerful tools for studying immune cell functions like cytotoxicity and cytokine production.
- They represent an innovative immunotherapy for cancer treatment by bridging target and immune cells.
Purpose of the Study:
- To review the mechanisms and applications of bispecific antibodies in cancer immunotherapy.
- To discuss the distinct lymphocyte populations and bispecific antibody preparations used in this approach.
Main Methods:
- Utilizing the dual specificity of bispecific antibodies to recognize tumor-associated antigens and lymphocyte activation sites.
- Crosslinking of target and immune cells to trigger lymphocyte activation and lytic machinery.
Main Results:
- Bispecific antibodies activate lymphocytes, leading to cytokine production and enhanced cellular cytotoxicity.
- This approach leverages the natural cellular immune defense system, resulting in reduced toxicity.
Conclusions:
- Bispecific antibodies offer a potent and less toxic immunotherapy strategy for cancer.
- The review covers various lymphocyte populations, antibody preparations, and chimeric constructs for adoptive immunotherapy.